Session 1F: The Role of Hedgehog/ GLI in T-cell Lymphoma
Session Number
Session 1F: 1st Presentation
Advisor(s)
Sherine Elsawa, Northern Illinois University
Location
Room A115
Start Date
28-4-2017 8:30 AM
End Date
28-4-2017 9:45 AM
Abstract
This experiment was performed to determine the role of the Hedgehog (HH) signalling pathway and transcription factors GLI, specifically GLI 1, 2, and 3, in T-cell lymphoma. Using this knowledge we determined which drugs- both alone and in combination- were most effective as therapies. Lymphoma is an aggressive form of cancer that occurs after the abnormal growth of white blood cells called lymphocytes. There are two main types of lymphocytes that can develop into lymphomas: Blymphocytes (B-cells) and T-lymphocytes (T-cells). This project focused on T-cell lymphoma (TCL). Different drugs were used individually on 7 different TCL cell lines including GANT 61, Ibrutinib, Bortezomib, Cyclopamine, Romidepsin, Panobinostat (LBH). Combinations were also tested: GANT with Ibrutinib, GANT with Bortezomib, GANT with Romidepsin, and GANT with LBH. This was done to determine the effects of inhibiting aspects of the HH signalling pathway and whether combining treatments decreased cell proliferation. This was done through XTT proliferation assay, RNA isolation and quantification, cDNA synthesis, and Polymerase Chain Reaction (PCR). These were used to study TCL cell proliferation and the effects of hH gene expression in the cells. The results showed reduced cell proliferation when using GANT 61 or Romidepsin as a treatment.
Session 1F: The Role of Hedgehog/ GLI in T-cell Lymphoma
Room A115
This experiment was performed to determine the role of the Hedgehog (HH) signalling pathway and transcription factors GLI, specifically GLI 1, 2, and 3, in T-cell lymphoma. Using this knowledge we determined which drugs- both alone and in combination- were most effective as therapies. Lymphoma is an aggressive form of cancer that occurs after the abnormal growth of white blood cells called lymphocytes. There are two main types of lymphocytes that can develop into lymphomas: Blymphocytes (B-cells) and T-lymphocytes (T-cells). This project focused on T-cell lymphoma (TCL). Different drugs were used individually on 7 different TCL cell lines including GANT 61, Ibrutinib, Bortezomib, Cyclopamine, Romidepsin, Panobinostat (LBH). Combinations were also tested: GANT with Ibrutinib, GANT with Bortezomib, GANT with Romidepsin, and GANT with LBH. This was done to determine the effects of inhibiting aspects of the HH signalling pathway and whether combining treatments decreased cell proliferation. This was done through XTT proliferation assay, RNA isolation and quantification, cDNA synthesis, and Polymerase Chain Reaction (PCR). These were used to study TCL cell proliferation and the effects of hH gene expression in the cells. The results showed reduced cell proliferation when using GANT 61 or Romidepsin as a treatment.